Skip to main content
Fig. 4 | BMC Neurology

Fig. 4

From: Immunogenicity, clinical efficacy, and safety of the sinopharm (BBIBP-CorV) SARS-CoV-2 vaccine among people with multiple sclerosis receiving disease-modifying therapies: a prospective cohort study

Fig. 4

The relationships between the levels of SARS-CoV-2 neutralizing Ab, anti-nucleocapsid IgG, and anti-spike IgG and numeric variables were determined using the Locally Weighted Least Squares Regression (loess) method. Abbreviations: Ab: antibody; EDSS: expanded disability status scale; IgG: immunoglobulin G; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2

Back to article page

BMC Neurology

ISSN: 1471-2377

Contact us